Novel Naturally Occurring Autoantibodies Attenuate Α‐synuclein Pathology in a Mouse Model of Parkinson's Disease

Yiming Li,Tao Wang,Lanxia Meng,Lei Jin,Congcong Liu,Yangqiu Liang,Lin Ren,Yang Liu,Yanshuang Liu,Shuang Liu,Tete Li,Yanqi Liang,Xiaoping Chen,Zhentao Zhang
DOI: https://doi.org/10.1111/nan.12860
2022-01-01
Neuropathology and Applied Neurobiology
Abstract:Aims: Accumulation and propagation of pathological alpha-synuclein (alpha-Syn) are the major contributing factors to the pathogenesis of Parkinson's disease (PD). Therapy to halt the spreading of alpha-Syn pathology needs to be established. Methods: After phage display and affinity maturation, human-derived anti-alpha-Syn autoantibodies were selected and applied to biochemical, cellular and animal models of PD. Results: The novel naturally occurring anti-alpha-Syn autoantibodies (alpha-Syn-nAbs), P21 and P22, selectively bind alpha-Syn preformed fibrils (PFFs), recognise Lewy bodies (LBs) and Lewy neurites (LNs) in human PD brains, block a-Syn fibrillization and inhibit the seeding of alpha-Syn PFFs. Moreover, systematic administration of P21 and P22 attenuates alpha-Syn pathology, degeneration of the nigrostriatal pathway and motor deficits in mice injected with alpha-Syn PFFs. Conclusions: P21 and P22 attenuate alpha-synuclein pathology and are promising candidates for PD treatment.
What problem does this paper attempt to address?